Lucid Diagnostics (LUCD) Secures VA Contract for EsoGuard Esophageal DNA Test at Medicare Pricing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Should l Buy LUCD?
Source: seekingalpha
- Contract Award: Lucid Diagnostics (LUCD) has secured a contract from the U.S. Department of Veterans Affairs, allowing it to offer the EsoGuard Esophageal DNA Test at Medicare pricing, which is expected to significantly enhance the company's competitiveness in the healthcare market.
- Market Expansion: This contract enables Lucid to supply EsoGuard through a single, national VA procurement framework, further solidifying its market position within the largest integrated healthcare system in the U.S., likely leading to increased sales and market share.
- Strategic Partnership: Lucid's COO Shaun O'Neil remarked that the partnership with the U.S. Department of Veterans Affairs will expand veterans' access to EsoGuard, demonstrating the company's commitment to improving veterans' health and enhancing its brand image.
- Stock Price Reaction: Following the contract announcement, Lucid's stock rose approximately 10% in premarket trading, reflecting the market's positive response to this significant contract, which may drive future investments and growth for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LUCD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LUCD
Wall Street analysts forecast LUCD stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.440
Low
3.00
Averages
4.05
High
8.25
Current: 1.440
Low
3.00
Averages
4.05
High
8.25
About LUCD
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Supreme Court Strikes Down Trump's Tariffs, New 15% Levy Announced
- Tariff Policy Reversal: The U.S. Supreme Court ruled 6-3 to strike down Trump's tariffs, stating that the current law does not authorize the President to impose such duties, potentially obligating the U.S. government to refund over $175 billion to importers, undermining Trump's economic policy foundation.
- New Tariff Implementation: Following the ruling, Trump announced a new global 10% tariff, which he raised to 15% the next day, provoking strong backlash from Congressional Democrats and international trading partners, which could disrupt trade negotiations with countries like India.
- Market Reaction: Although the court's decision surprised Wall Street, stocks rose after the ruling, helping major indexes finish the week positively; however, stock futures fell this morning as investors weighed the implications of Trump's new tariff policy.
- Airline Industry Impact: A blizzard warning in the Northeast led to 15% of scheduled U.S. flights being canceled on Monday, as airlines faced operational challenges during the busy winter holiday period, highlighting the direct economic impact of extreme weather conditions.
See More
PAVmed Secures $30 Million in Series D Preferred Stock Offering
- Successful Financing: PAVmed has raised $30 million through the issuance of Series D Preferred Stock, which includes warrants that could yield an additional $30 million, significantly enhancing the company's capital base to support future business expansion.
- Capital Structure Optimization: The proceeds from this financing will be used to redeem all outstanding Series C Preferred Stock, eliminating a significant legacy capital structure overhang, thereby unlocking asset potential for shareholders and improving financial health.
- Cash Flow Enhancement: Following the financing transaction, PAVmed expects to add approximately $7.7 million in net cash flow, further strengthening its balance sheet and enhancing its competitiveness in the medical technology sector.
- Strategic Development Outlook: The company plans to convene a special meeting of shareholders by April 2026 to seek approval for converting the preferred stock into common stock, which, if successful, will provide greater flexibility and funding support for future growth.
See More
PAVmed Subsidiary Secures VA Contract for EsoGuard Test, Expanding Access to Over 9 Million Veterans
- Contract Approval: Lucid Diagnostics has secured a contract with the Department of Veterans Affairs for its EsoGuard test, significantly enhancing access across the nationwide healthcare system serving over 9 million veterans, thereby strengthening the company's competitive position in the healthcare market.
- Standardized Procurement: The contract allows VA hospitals to procure EsoGuard through a unified framework, ensuring pre-negotiated pricing aligned with Medicare payment standards, which simplifies the procurement process and reduces operational costs.
- Clinical Evidence Support: Lucid stated that the award reflects the clinical evidence supporting the EsoGuard test, further solidifying its potential for integration into standard clinical practice and possibly facilitating collaborations with other integrated health systems.
- Market Performance Analysis: PAVmed shares are currently trading at $11.46, 40.4% above the 20-day simple moving average but 0.8% below the 100-day average, indicating strong short-term performance but potential long-term weakness in market signals.
See More
Lucid Diagnostics Secures VA Contract for EsoGuard, Boosting PAVmed Stock by 291%
- Contract Approval: Lucid Diagnostics has secured a contract from the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, expanding access to esophageal precancer testing for over nine million veterans, which is expected to significantly enhance the company's influence in the healthcare market.
- Pricing Advantage: The contract includes pre-negotiated pricing aligned with Medicare payment rates, allowing VA facilities to procure EsoGuard through a streamlined process, further strengthening the product's market competitiveness.
- Stock Performance: PAVmed's stock surged by 291.11% to $17.80 on Wednesday, reflecting strong short-term market performance and aligning with the positive trends in the Nasdaq and S&P 500 indices.
- Technical Indicators: PAVmed is currently trading 167.1% above its 20-day simple moving average, indicating strong short-term technical indicators; although the relative strength index (RSI) is in neutral territory, the MACD shows bullish momentum, suggesting optimistic market sentiment.
See More
PAVmed Subsidiary Wins VA Contract for Esophageal Precancer Testing, Shares Surge 250%
- Contract Approval: PAVmed's subsidiary, Lucid Diagnostics, secured a contract from the U.S. Department of Veterans Affairs to provide the EsoGuard Esophageal DNA Test, granting access to over nine million enrolled veterans, significantly enhancing the company's influence in the medical testing market.
- Stock Surge: PAVM shares skyrocketed over 250% on Wednesday morning, becoming a trending stock on Stocktwits, reflecting strong market optimism regarding the contract and potentially attracting more investor interest.
- Market Reaction: Following the contract announcement, retail sentiment for PAVM flipped from 'bearish' to 'extremely bullish', with message volumes surging, indicating increased investor confidence in the company's growth potential.
- Clinical Evidence Support: The President of Lucid Diagnostics stated that the VA's selection of EsoGuard reflects the strength of its clinical evidence, further solidifying the company's market position in early cancer prevention diagnostics.
See More
Lucid Diagnostics (LUCD) Secures VA Contract for EsoGuard Esophageal DNA Test at Medicare Pricing
- Contract Award: Lucid Diagnostics (LUCD) has secured a contract from the U.S. Department of Veterans Affairs, allowing it to offer the EsoGuard Esophageal DNA Test at Medicare pricing, which is expected to significantly enhance the company's competitiveness in the healthcare market.
- Market Expansion: This contract enables Lucid to supply EsoGuard through a single, national VA procurement framework, further solidifying its market position within the largest integrated healthcare system in the U.S., likely leading to increased sales and market share.
- Strategic Partnership: Lucid's COO Shaun O'Neil remarked that the partnership with the U.S. Department of Veterans Affairs will expand veterans' access to EsoGuard, demonstrating the company's commitment to improving veterans' health and enhancing its brand image.
- Stock Price Reaction: Following the contract announcement, Lucid's stock rose approximately 10% in premarket trading, reflecting the market's positive response to this significant contract, which may drive future investments and growth for the company.
See More
Supreme Court Strikes Down Trump's Tariffs, New 15% Levy Announced
- Tariff Policy Reversal: The U.S. Supreme Court ruled 6-3 to strike down Trump's tariffs, stating that the current law does not authorize the President to impose such duties, potentially obligating the U.S. government to refund over $175 billion to importers, undermining Trump's economic policy foundation.
- New Tariff Implementation: Following the ruling, Trump announced a new global 10% tariff, which he raised to 15% the next day, provoking strong backlash from Congressional Democrats and international trading partners, which could disrupt trade negotiations with countries like India.
- Market Reaction: Although the court's decision surprised Wall Street, stocks rose after the ruling, helping major indexes finish the week positively; however, stock futures fell this morning as investors weighed the implications of Trump's new tariff policy.
- Airline Industry Impact: A blizzard warning in the Northeast led to 15% of scheduled U.S. flights being canceled on Monday, as airlines faced operational challenges during the busy winter holiday period, highlighting the direct economic impact of extreme weather conditions.
See More
PAVmed Secures $30 Million in Series D Preferred Stock Offering
- Successful Financing: PAVmed has raised $30 million through the issuance of Series D Preferred Stock, which includes warrants that could yield an additional $30 million, significantly enhancing the company's capital base to support future business expansion.
- Capital Structure Optimization: The proceeds from this financing will be used to redeem all outstanding Series C Preferred Stock, eliminating a significant legacy capital structure overhang, thereby unlocking asset potential for shareholders and improving financial health.
- Cash Flow Enhancement: Following the financing transaction, PAVmed expects to add approximately $7.7 million in net cash flow, further strengthening its balance sheet and enhancing its competitiveness in the medical technology sector.
- Strategic Development Outlook: The company plans to convene a special meeting of shareholders by April 2026 to seek approval for converting the preferred stock into common stock, which, if successful, will provide greater flexibility and funding support for future growth.
See More
PAVmed Subsidiary Secures VA Contract for EsoGuard Test, Expanding Access to Over 9 Million Veterans
- Contract Approval: Lucid Diagnostics has secured a contract with the Department of Veterans Affairs for its EsoGuard test, significantly enhancing access across the nationwide healthcare system serving over 9 million veterans, thereby strengthening the company's competitive position in the healthcare market.
- Standardized Procurement: The contract allows VA hospitals to procure EsoGuard through a unified framework, ensuring pre-negotiated pricing aligned with Medicare payment standards, which simplifies the procurement process and reduces operational costs.
- Clinical Evidence Support: Lucid stated that the award reflects the clinical evidence supporting the EsoGuard test, further solidifying its potential for integration into standard clinical practice and possibly facilitating collaborations with other integrated health systems.
- Market Performance Analysis: PAVmed shares are currently trading at $11.46, 40.4% above the 20-day simple moving average but 0.8% below the 100-day average, indicating strong short-term performance but potential long-term weakness in market signals.
See More
Lucid Diagnostics Secures VA Contract for EsoGuard, Boosting PAVmed Stock by 291%
- Contract Approval: Lucid Diagnostics has secured a contract from the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, expanding access to esophageal precancer testing for over nine million veterans, which is expected to significantly enhance the company's influence in the healthcare market.
- Pricing Advantage: The contract includes pre-negotiated pricing aligned with Medicare payment rates, allowing VA facilities to procure EsoGuard through a streamlined process, further strengthening the product's market competitiveness.
- Stock Performance: PAVmed's stock surged by 291.11% to $17.80 on Wednesday, reflecting strong short-term market performance and aligning with the positive trends in the Nasdaq and S&P 500 indices.
- Technical Indicators: PAVmed is currently trading 167.1% above its 20-day simple moving average, indicating strong short-term technical indicators; although the relative strength index (RSI) is in neutral territory, the MACD shows bullish momentum, suggesting optimistic market sentiment.
See More
PAVmed Subsidiary Wins VA Contract for Esophageal Precancer Testing, Shares Surge 250%
- Contract Approval: PAVmed's subsidiary, Lucid Diagnostics, secured a contract from the U.S. Department of Veterans Affairs to provide the EsoGuard Esophageal DNA Test, granting access to over nine million enrolled veterans, significantly enhancing the company's influence in the medical testing market.
- Stock Surge: PAVM shares skyrocketed over 250% on Wednesday morning, becoming a trending stock on Stocktwits, reflecting strong market optimism regarding the contract and potentially attracting more investor interest.
- Market Reaction: Following the contract announcement, retail sentiment for PAVM flipped from 'bearish' to 'extremely bullish', with message volumes surging, indicating increased investor confidence in the company's growth potential.
- Clinical Evidence Support: The President of Lucid Diagnostics stated that the VA's selection of EsoGuard reflects the strength of its clinical evidence, further solidifying the company's market position in early cancer prevention diagnostics.
See More
Lucid Diagnostics (LUCD) Secures VA Contract for EsoGuard Esophageal DNA Test at Medicare Pricing
- Contract Award: Lucid Diagnostics (LUCD) has secured a contract from the U.S. Department of Veterans Affairs, allowing it to offer the EsoGuard Esophageal DNA Test at Medicare pricing, which is expected to significantly enhance the company's competitiveness in the healthcare market.
- Market Expansion: This contract enables Lucid to supply EsoGuard through a single, national VA procurement framework, further solidifying its market position within the largest integrated healthcare system in the U.S., likely leading to increased sales and market share.
- Strategic Partnership: Lucid's COO Shaun O'Neil remarked that the partnership with the U.S. Department of Veterans Affairs will expand veterans' access to EsoGuard, demonstrating the company's commitment to improving veterans' health and enhancing its brand image.
- Stock Price Reaction: Following the contract announcement, Lucid's stock rose approximately 10% in premarket trading, reflecting the market's positive response to this significant contract, which may drive future investments and growth for the company.
See More
